Drug Profile
Lisuride - axxonis
Alternative Names: Lisuride - subcutaneous; Lisuride - transdermal; Lisuride maleate; Lisuride Sub Q; Lisuride TDS; Lysuride; NenadLatest Information Update: 19 Apr 2015
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer axxonis Pharma
- Class Antimigraines; Antiparkinsonians; Ergolines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2B receptor antagonists; Serotonin 2C receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Restless legs syndrome
- No development reported Parkinson's disease
Most Recent Events
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
- 18 Feb 2010 Lisuride is still in preregistration stage for Parkinson's disease in Switzerland
- 07 Jan 2010 Suspended - Preregistration for Restless legs syndrome in European Union (Transdermal)